Aggregated News
Salt Lake City-based Myriad Genetics sells a test to screen for dangerous variants of the BRCA1 and BRCA2 genes, which are associated with increased risks of breast and ovarian cancer. On Thursday, the U.S. Federal Court of Appeals in Washington, D.C., upheld the gene patent — but held that some processes related to analyzing gene patents may not have protection.
Pete Corless is a Boston-based partner at Edwards Wildman Palmer, a law firm that represents patent holders — including the National Institutes of Health, universities and biotech companies — in intellectual property cases. He views the appeals court’s decision as a mixed result.
What did the court decide?
Myriad has patents on isolated DNA sequences that correspond in various respects to sequences you would find in the human body. It also has patents on manipulated forms of those sequences.
The court said all of those were patentable subject matter. That’s...